Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boehringer Ingelheim reported the data from a pre-specified interim analysis of a Phase IIb study, Sound-C2, which assessed the company's two investigational HCV direct-acting antivirals.
Subscribe to our email newsletter
The study demonstrated that the combination of two oral direct acting anti hepatitis C virus (HCV) compounds (the protease inhibitor BI 201335 and the polymerase inhibitor BI 207127, with and without ribavirin (RBV), could provide virological response rates at week 12 in treatment-naïve patients infected with the most difficult to treat genotype-1.
BI 201335 is an investigational oral HCV NS3/4A protease inhibitor, which has completed clinical trials through Phase IIb (SILEN-C studies)
All five treatment arms of the interferon-free oral combination therapy of BI 201335/BI 207127/RBV showed high virologic response rates through week 12, defined by measuring the level of HCV RNA in patient blood.